The New Frontiers of Gene Therapy and Gene Editing in Inflammatory Diseases

Romano, Alessandro; Mortellaro, Alessandra

doi:10.1089/hum.2023.210

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Addressing defective autophagy holds promise in modulating the development of IBD, thus restoring intestinal homeostasis, rebalancing the gut microbiota, and improving the clearance of intracellular pathogens. Innovative therapies targeting autophagy pathways, such as dietary interventions[ 16 ] and gene therapies[ 17 ], may offer potential avenues for advancements in personalized IBD management and treatment.…”

Section: To the Editormentioning

confidence: 99%

More on the interplay between gut microbiota, autophagy, and inflammatory bowel disease is needed

Subramanian,

Jahabardeen,

Thamaraikani

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

The concept of inflammatory bowel disease (IBD), which encompasses Crohn’s disease and ulcerative colitis, represents a complex and growing global health concern resulting from a multifactorial etiology. Both dysfunctional autophagy and dysbiosis contribute to IBD, with their combined effects exacerbating the related inflammatory condition. As a result, the existing interconnection between gut microbiota, autophagy, and the host’s immune system is a decisive factor in the occurrence of IBD. The factors that influence the gut microbiota and their impact are another important point in this regard. Based on this initial perspective, this manuscript briefly highlighted the intricate interplay between the gut microbiota, autophagy, and IBD pathogenesis. In addition, it also addressed the potential targeting of the microbiota and modulating autophagic pathways for IBD therapy and proposed suggestions for future research within a more specific and expanded context. Further studies are warranted to explore restoring microbial balance and regulating autophagy mechanisms, which may offer new therapeutic avenues for IBD management and to delve into personalized treatment to alleviate the related burden.

show abstract

Section: To the Editormentioning

confidence: 99%

More on the interplay between gut microbiota, autophagy, and inflammatory bowel disease is needed

Subramanian,

Jahabardeen,

Thamaraikani

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

Comparing the Diagnostic Value of FDG PET or PET/CT With FDG PET/MR in Inflammatory Bowel Disease—A Systematic Review and Meta-analysis

Lin,

Chang,

Kao

2024

Clin Nucl Med

View full text Add to dashboard Cite

Background The aim of this study was to compare the diagnostic value of 18F-FDG PET or PET/CT with FDG PET/MR in patients with inflammatory bowel disease (IBD). Methods A comprehensive search was performed in PubMed for studies reporting the diagnostic performance of FDG PET (PET/CT) and FDG PET/MR in IBD from the inception of the database to March 14, 2024, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Fourteen studies were included in this systematic review and meta-analysis. Pooled estimates of segment-based sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio for FDG PET (PET/CT) and FDG PET/MR were calculated alongside 95% confidence intervals. Summary receiver operating characteristic (SROC) curves were plotted, and the area under the SROC curve was determined alongside the Q* index. Results The segment-based pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the SROC curve of FDG PET (PET/CT) for diagnosing IBD (9 studies) were 0.81, 0.86, 5.76, 0.22, 31.92, and 0.92, respectively. Those of FDG PET/MR (5 studies) were 0.78, 0.92, 10.97, 0.25, 51.79, and 0.95. There was no significant difference in the abilities of detecting or excluding IBD between FDG PET (PET/CT) and FDG PET/MR. Conclusions For diagnostic value in patients with IBD, there was no significant difference between FDG PET (PET/CT) and FDG PET/MR. Both FDG PET (PET/CT) and FDG PET/MR have demonstrated high diagnostic performance for accurate diagnosing in patients with IBD.

show abstract

The New Frontiers of Gene Therapy and Gene Editing in Inflammatory Diseases

Cited by 2 publications

References 53 publications

More on the interplay between gut microbiota, autophagy, and inflammatory bowel disease is needed

More on the interplay between gut microbiota, autophagy, and inflammatory bowel disease is needed

Comparing the Diagnostic Value of FDG PET or PET/CT With FDG PET/MR in Inflammatory Bowel Disease—A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About